Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,809.74 -2,386.65 (-3.78%) CMC Crypto 200
1,257.59 -100.42 (-7.40%)
Novartis AG (NVSEF)
| Previous close | 96.68 |
| Open | 101.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 101.90 - 101.99 |
| 52-week range | 90.12 - 109.00 |
| Volume | |
| Avg. volume | 42,467 |
| Market cap | 214.612B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 23.18 |
| EPS (TTM) | 4.40 |
| Earnings date | 18 Jul 2024 |
| Forward dividend & yield | 3.76 (3.89%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
GlobeNewswireArvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
The TelegraphQuestor: this medical stock is expensive – but worth paying for
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.
ZacksAlnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
